Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Raw Materials: 2021-2025

Historic Raw Materials for Mirum Pharmaceuticals (MIRM) over the last 2 years, with Sep 2025 value amounting to $2.9 million.

  • Mirum Pharmaceuticals' Raw Materials rose 2.83% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 2.83%. This contributed to the annual value of $3.0 million for FY2024, which is 1.07% up from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported Raw Materials of $2.9 million as of Q3 2025, which was down 1.85% from $2.9 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' Raw Materials' 5-year high stood at $3.0 million during Q4 2024, with a 5-year trough of $444,000 in Q3 2023.
  • Moreover, its 3-year median value for Raw Materials was $2.9 million (2024), whereas its average is $2.6 million.
  • Data for Mirum Pharmaceuticals' Raw Materials shows a peak YoY spiked of 528.38% (in 2024) over the last 5 years.
  • Mirum Pharmaceuticals' Raw Materials (Quarterly) stood at $856,000 in 2021, then reached $858,000 in 2022, then reached $3.0 million in 2023, then climbed by 1.07% to $3.0 million in 2024, then climbed by 2.83% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q3 2025, $2.9 million for Q2 2025, and $3.0 million during Q1 2025.